AngioDynamics in Pivotal Point Check: 22% Revenue Growth in Q3 - NanoKnife and Thrombectomy Drive MedTech Segment!
Reading Time: 2 minutes
Strategic focus on expanding the MedTech offering leads to an impressive revenue growth of 22.2% in this segment. Credit line of $25 million increases financial flexibility. NanoKnife and thrombectomy are expected to generate revenues of $285 to $288 million in the fiscal year 2025. The medical technology company reported earnings per share of $0.03 for the third quarter on April 2, 2025. This surpassed analyst estimates of negative $0.11 by $0.14. Quarterly revenue reached $72 million, exceeding consensus estimates of $70.57 million....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
